[{"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-001", "question": "A 6-year-old boy with a history of Diamond-Blackfan anemia (DBA) treated with chronic corticosteroids and transfusions presents with progressive dyspnea and fatigue. Echocardiography reveals a restrictive cardiomyopathy with severe biventricular diastolic dysfunction and moderate pulmonary hypertension. Genetic testing confirms a pathogenic variant in RPS19. Which of the following is the most appropriate next step in management?", "options": ["Initiation of high-dose beta-blockers and ACE inhibitors", "Referral for combined heart-lung transplantation evaluation", "Immediate discontinuation of corticosteroids and transition to defibrotide", "Addition of L-leucine supplementation to current regimen", "Cardiac MRI with T1 mapping and extracellular volume quantification"], "answer": "D", "answer_index": 3, "explanation": "Diamond-Blackfan anemia is associated with ribosomal protein mutations, and L-leucine has been shown to improve ribosomal function and hematopoiesis in DBA. In patients with DBA-associated cardiomyopathy, addressing the underlying ribosomal dysfunction with leucine supplementation may improve cardiac function, whereas conventional heart failure therapies are less effective for this specific pathophysiology. Beta-blockers/ACE inhibitors would be insufficient, transplantation is premature without addressing the underlying metabolic defect, defibrotide is for hepatic veno-occlusive disease, and advanced imaging would not change management.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "To answer this question, I need to consider the clinical presentation and the underlying condition.\n\nThe patient has Diamond-Blackfan anemia (DBA) with a confirmed RPS19 mutation, which is a classic genetic cause of DBA. He has developed restrictive cardiomyopathy with diastolic dysfunction and pulmonary hypertension.\n\nLet me analyze each option:\n\nA. Beta-blockers and ACE inhibitors - These medications can worsen restrictive cardiomyopathy by reducing preload and cardiac output, and are generally not first-line therapy for restrictive cardiomyopathy.\n\nB. Heart-lung transplantation evaluation - This would be a very aggressive approach without first determining the cause of the cardiomyopathy.\n\nC. Discontinuing corticosteroids and starting defibrotide - Defibrotide is used for hepatic veno-occlusive disease, not for cardiac complications of DBA.\n\nD. L-leucine supplementation - L-leucine has shown some promise in DBA by enhancing ribosome biogenesis, but it's not established as therapy for cardiac complications.\n\nE. Cardiac MRI with T1 mapping - This would help determine if the cardiomyopathy is due to iron overload (a common complication in chronically transfused patients), which would guide specific therapy.\n\nGiven the history of chronic transfusions, iron overload cardiomyopathy is a likely cause of the restrictive pattern. Before proceeding with aggressive interventions, determining if iron overload is the cause would be the most appropriate next step.\n\nThe answer is (E)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-002", "question": "A 34-year-old pregnant woman at 32 weeks gestation presents with acute-onset severe hypertension (200/120 mmHg), headache, and visual disturbances. Laboratory studies show thrombocytopenia (platelets 85,000/μL), elevated liver enzymes (AST 250 U/L, ALT 280 U/L), and creatinine 1.8 mg/dL. Magnesium sulfate is initiated. Despite aggressive antihypertensive therapy with labetalol and hydralazine, her blood pressure remains persistently elevated. Which of the following is the most appropriate next pharmacologic intervention?", "options": ["Immediate initiation of nitroprusside infusion", "Addition of oral nifedipine XL 30 mg daily", "Intravenous fenoldopam infusion titrated to effect", "Sublingual captopril 12.5 mg repeated every 30 minutes", "Intravenous esmolol bolus followed by continuous infusion"], "answer": "C", "answer_index": 2, "explanation": "Fenoldopam is a dopamine-1 receptor agonist that causes vasodilation without compromising uteroplacental blood flow and is safe in pregnancy for refractory hypertension. Nitroprusside is contraindicated due to risk of cyanide toxicity to the fetus. Nifedipine XL has slow onset and is inadequate for acute control. ACE inhibitors like captopril are contraindicated in pregnancy due to fetal renal toxicity. Esmolol may cause fetal bradycardia and is less ideal than fenoldopam for pregnancy-associated hypertensive emergencies.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to identify the condition and determine the most appropriate next pharmacologic intervention for refractory hypertension in this scenario.\n\nThe patient is presenting with:\n- Severe hypertension (200/120 mmHg)\n- Headache and visual disturbances\n- Thrombocytopenia (platelets 85,000/μL)\n- Elevated liver enzymes (AST 250 U/L, ALT 280 U/L)\n- Elevated creatinine (1.8 mg/dL)\n- 32 weeks gestation\n\nThis clinical picture is consistent with preeclampsia with severe features/HELLP syndrome. The patient has already received first-line antihypertensive therapy (labetalol and hydralazine) and magnesium sulfate for seizure prophylaxis, but her blood pressure remains uncontrolled.\n\nEvaluating the options:\nA. Nitroprusside - Generally avoided in pregnancy due to risk of fetal cyanide toxicity\nB. Nifedipine XL - Calcium channel blocker that can be used in pregnancy, but the oral route may not be fast enough for this emergency\nC. Fenoldopam - Dopamine receptor agonist that can lower blood pressure without decreasing renal blood flow\nD. Captopril - ACE inhibitors are contraindicated in pregnancy\nE. Esmolol - Beta-blocker with very short half-life, but adding another beta-blocker after labetalol may not be the best choice\n\nFor severe, refractory hypertension in preeclampsia when first-line agents have failed, intravenous calcium channel blockers or fenoldopam are reasonable next options. Fenoldopam has the advantage of maintaining or improving renal perfusion, which is particularly important given the patient's elevated creatinine.\n\nThe answer is (C)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-003", "question": "A 58-year-old man with metastatic renal cell carcinoma on nivolumab and ipilimumab combination therapy presents with acute respiratory failure requiring mechanical ventilation. Bronchoalveolar lavage shows lymphocytic predominance without infectious organisms. High-dose methylprednisolone (2 mg/kg/day) was initiated 72 hours ago without improvement. Which of the following is the most appropriate next step in management?", "options": ["Add infliximab 5 mg/kg single dose", "Initiate cyclophosphamide 1 g/m² IV", "Switch to dexamethasone 40 mg daily", "Begin plasma exchange therapy", "Add tocilizumab 8 mg/kg IV"], "answer": "A", "answer_index": 0, "explanation": "For steroid-refractory immune checkpoint inhibitor-related pneumonitis, TNF-alpha inhibition with infliximab is the recommended next-line therapy based on retrospective evidence showing improved outcomes. Cyclophosphamide is used for other immune-related adverse events like myocarditis but not first-line for pneumonitis. Switching corticosteroids is unlikely to help if already on high-dose methylprednisolone. Plasma exchange is not established for this condition. Tocilizumab (IL-6 inhibitor) is used for cytokine release syndrome but not specifically for checkpoint inhibitor pneumonitis.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To answer this question, I need to analyze a case of immune checkpoint inhibitor-related pneumonitis that is not responding to first-line therapy.\n\nThe patient has:\n- Metastatic renal cell carcinoma on nivolumab and ipilimumab (dual checkpoint inhibitor therapy)\n- Acute respiratory failure requiring mechanical ventilation\n- Lymphocytic predominance on BAL without infection\n- No improvement after 72 hours of high-dose methylprednisolone (2 mg/kg/day)\n\nThis represents severe (grade 3-4) immune-related pneumonitis that is steroid-refractory. According to treatment guidelines for immune-related adverse events:\n\n- First-line therapy is high-dose corticosteroids (already tried)\n- For steroid-refractory cases, additional immunosuppression is indicated\n- Infliximab (anti-TNF-α) is the recommended second-line agent for steroid-refractory pneumonitis\n- Switching between corticosteroids (option C) would not provide additional benefit\n- Cyclophosphamide is not typically used as second-line therapy for this condition\n- Plasma exchange is not indicated for immune checkpoint inhibitor pneumonitis\n- Tocilizumab (IL-6 inhibitor) has some evidence in COVID-19 pneumonia but is not the established second-line agent for checkpoint inhibitor pneumonitis\n\nThe answer is (A)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-004", "question": "A 3-day-old term neonate presents with poor feeding, lethargy, and hypoglycemia (glucose 25 mg/dL). Physical exam reveals macroglossia, umbilical hernia, and mild hepatomegaly. Newborn screening shows elevated galactose and galactitol. Which of the following additional findings would be most specific for confirming the diagnosis?", "options": ["Elevated serum ammonia level", "Absent reducing substances in urine after lactose challenge", "Normal glycogen content on liver biopsy", "Deficient activity of galactose-1-phosphate uridyltransferase in erythrocytes", "Presence of cataract on ophthalmologic examination"], "answer": "C", "answer_index": 2, "explanation": "The presentation suggests galactosemia, but the key distinguishing feature is that in galactose epimerase deficiency (a rare form), liver biopsy shows normal glycogen content, whereas in classic galactosemia (GALT deficiency), glycogen is depleted. Elevated ammonia suggests urea cycle defect. Absent reducing substances would argue against galactosemia. GALT enzyme deficiency confirms classic galactosemia, not the epimerase variant. Cataracts occur in both forms and are not specific.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "To determine the most specific finding for confirming the diagnosis in this case, I need to analyze the clinical presentation and laboratory findings.\n\nThe patient presents with:\n- Poor feeding, lethargy, hypoglycemia\n- Macroglossia, umbilical hernia, hepatomegaly\n- Elevated galactose and galactitol on newborn screening\n\nThese findings strongly suggest galactosemia, a disorder of galactose metabolism. Let's evaluate each option:\n\nA. Elevated serum ammonia - While this can occur in some metabolic disorders, it's not specific for galactosemia.\n\nB. Absent reducing substances in urine after lactose challenge - This would not be expected in galactosemia; patients with galactosemia would typically have positive reducing substances.\n\nC. Normal glycogen content on liver biopsy - Not specific for galactosemia.\n\nD. Deficient activity of galactose-1-phosphate uridyltransferase in erythrocytes - This is the enzymatic defect in classic galactosemia and would be the most specific confirmatory test.\n\nE. Presence of cataract - While cataracts can occur in galactosemia, they are not as specific as the enzyme assay for diagnosis.\n\nThe answer is (D)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-005", "question": "A 42-year-old woman with systemic lupus erythematosus and antiphospholipid syndrome on warfarin (INR 2.5-3.5) presents with acute right leg pain and swelling. Doppler ultrasound confirms extensive deep vein thrombosis despite therapeutic anticoagulation. Lupus anticoagulant is positive, and anti-β2-glycoprotein I antibodies are elevated. Which of the following management strategies is most appropriate?", "options": ["Switch to rivaroxaban 20 mg daily", "Increase warfarin target INR to 3.5-4.5", "Add hydroxychloroquine 400 mg daily to current regimen", "Initiate intravenous immunoglobulin 1 g/kg for two days", "Place an inferior vena cava filter"], "answer": "C", "answer_index": 2, "explanation": "In antiphospholipid syndrome with breakthrough thrombosis despite therapeutic warfarin, adding hydroxychloroquine has been shown to reduce thrombotic risk through multiple mechanisms including inhibition of platelet activation and neutralization of antiphospholipid antibodies. Direct oral anticoagulants like rivaroxaban are less effective in triple-positive APS. Higher INR targets increase bleeding risk without proven benefit. IVIG is reserved for catastrophic APS. IVC filters do not address the hypercoagulable state and increase long-term DVT risk.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to consider the management of recurrent thrombosis in a patient with antiphospholipid syndrome (APS) despite therapeutic anticoagulation.\n\nThe patient has:\n- Systemic lupus erythematosus and antiphospholipid syndrome\n- Currently on warfarin with therapeutic INR (2.5-3.5)\n- Developed DVT despite adequate anticoagulation\n- Positive lupus anticoagulant and elevated anti-β2-glycoprotein I antibodies\n\nLet me evaluate each option:\n\nA. Switch to rivaroxaban - DOACs like rivaroxaban are generally not recommended for APS, especially in triple-positive patients (those with multiple positive antibodies).\n\nB. Increase warfarin target INR to 3.5-4.5 - This is a standard approach for recurrent thrombosis in APS despite therapeutic anticoagulation.\n\nC. Add hydroxychloroquine - While hydroxychloroquine has antithrombotic properties in SLE and APS, it's typically not the first-line response to acute thrombosis despite anticoagulation.\n\nD. IVIG - Not typically indicated for thrombotic APS management.\n\nE. IVC filter - Generally avoided unless there are contraindications to anticoagulation, which isn't the case here.\n\nFor patients with APS who develop recurrent thrombosis despite therapeutic anticoagulation, intensifying anticoagulation by increasing the target INR is the most appropriate next step.\n\nThe answer is (B)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-006", "question": "A 67-year-old man with ischemic cardiomyopathy (LVEF 25%) and cardiac resynchronization therapy defibrillator presents with recurrent appropriate shocks for ventricular tachycardia. He is on maximally tolerated doses of carvedilol, lisinopril, and spironolactone. Amiodarone was started but discontinued due to thyroid toxicity. Which of the following is the most appropriate next antiarrhythmic therapy?", "options": ["Mexiletine 200 mg three times daily", "Sotalol 80 mg twice daily", "Dofetilide 500 mcg twice daily with inpatient initiation", "Ranolazine 1000 mg twice daily", "Propafenone 150 mg three times daily"], "answer": "C", "answer_index": 2, "explanation": "Dofetilide is a class III antiarrhythmic that is effective for ventricular tachycardia in structural heart disease and does not have the non-cardiac toxicity profile of amiodarone. It requires inpatient initiation due to risk of torsades de pointes. Mexiletine has limited efficacy as monotherapy. Sotalol is contraindicated in severe systolic dysfunction. Ranolazine has antianginal but limited antiarrhythmic evidence for VT. Propafenone is contraindicated in structural heart disease due to proarrhythmic risk.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To determine the most appropriate antiarrhythmic therapy for this patient with ischemic cardiomyopathy and recurrent VT despite optimal medical therapy, I need to consider:\n\n1) The patient has severe LV dysfunction (LVEF 25%)\n2) He has already failed amiodarone due to thyroid toxicity\n3) He needs an antiarrhythmic that is safe in heart failure\n\nAnalyzing each option:\n\nA. Mexiletine (Class IB): Can be used in structural heart disease and has minimal hemodynamic effects. Often used as adjunctive therapy for VT.\n\nB. Sotalol (Class III): Contraindicated in severe heart failure due to negative inotropic effects and risk of torsades de pointes in patients with reduced ejection fraction.\n\nC. Dofetilide (Class III): Can be safely used in heart failure patients and has been shown to be effective for ventricular arrhythmias. Requires inpatient initiation for QT monitoring.\n\nD. Ranolazine: Has some antiarrhythmic properties but not FDA-approved or typically used as primary therapy for ventricular arrhythmias.\n\nE. Propafenone (Class IC): Contraindicated in structural heart disease due to increased mortality risk.\n\nFor a patient with severe LV dysfunction and recurrent VT, dofetilide is the most appropriate option among those listed, as it can be safely used in heart failure patients.\n\nThe answer is (C)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-007", "question": "A 28-year-old primigravida at 36 weeks gestation presents with progressive dyspnea and orthopnea. Echocardiography shows peripartum cardiomyopathy with LVEF 30%. After diuresis with furosemide, she remains symptomatic. Which of the following medications should be avoided until after delivery?", "options": ["Digoxin 0.125 mg daily", "Hydralazine 25 mg three times daily", "Isosorbide dinitrate 20 mg three times daily", "Sacubitril/valsartan 24/26 mg twice daily", "Metoprolol succinate 25 mg daily"], "answer": "D", "answer_index": 3, "explanation": "Sacubitril/valsartan contains an ARB (valsartan) which is contraindicated in pregnancy due to fetal renal toxicity and oligohydramnios risk, particularly in the third trimester. Digoxin, hydralazine, isosorbide dinitrate, and metoprolol are all acceptable in pregnancy for heart failure management. While ACE inhibitors and ARBs are absolutely contraindicated, the other medications listed can be used with appropriate monitoring.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "To answer this question, I need to consider which medication would be contraindicated in pregnancy, particularly at 36 weeks gestation in a patient with peripartum cardiomyopathy.\n\nAnalyzing each option:\n\nA. Digoxin - Generally considered safe in pregnancy (Category C) and can be used for heart failure.\n\nB. Hydralazine - Safe in pregnancy (Category C) and commonly used for heart failure and hypertension during pregnancy.\n\nC. Isosorbide dinitrate - Generally considered acceptable in pregnancy (Category C) when benefits outweigh risks.\n\nD. Sacubitril/valsartan - Contains valsartan, which is an angiotensin II receptor blocker (ARB). ARBs are contraindicated in pregnancy (Category D in 2nd and 3rd trimesters) due to risk of fetal renal damage, oligohydramnios, and other fetal complications.\n\nE. Metoprolol succinate - Beta-blockers are generally considered acceptable in pregnancy (Category C) and are used for heart failure.\n\nThe medication that should be avoided until after delivery is sacubitril/valsartan due to the ARB component.\n\nThe answer is (D)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-008", "question": "A 5-year-old girl with history of recurrent sinopulmonary infections presents with new-onset ataxia and nystagmus. MRI brain shows diffuse cerebellar atrophy. Serum immunoglobulin levels reveal IgG 450 mg/dL, IgA 10 mg/dL, and IgM 15 mg/dL. Flow cytometry shows absent B cells. Which of the following genetic mutations is most likely responsible for this clinical presentation?", "options": ["BTK gene mutation", "CD40 ligand deficiency", "AICDA gene mutation", "RAG1 gene mutation", "ATM gene mutation"], "answer": "E", "answer_index": 4, "explanation": "Ataxia-telangiectasia (ATM gene mutation) presents with combined immunodeficiency (low immunoglobulins, absent B cells), recurrent infections, cerebellar ataxia, and oculomotor apraxia. BTK mutation causes X-linked agammaglobulinemia with absent B cells but no ataxia. CD40 ligand deficiency causes hyper-IgM syndrome with normal or increased IgM. AICDA mutation causes hyper-IgM syndrome type 2. RAG1 mutation causes severe combined immunodeficiency (SCID) but not typically with cerebellar atrophy.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "To determine the most likely genetic mutation responsible for this clinical presentation, I'll analyze the key features:\n\n1) 5-year-old girl with recurrent sinopulmonary infections\n2) New-onset ataxia and nystagmus\n3) MRI showing cerebellar atrophy\n4) Low immunoglobulins across all classes (IgG, IgA, IgM)\n5) Absent B cells on flow cytometry\n\nLooking at each option:\n\nA. BTK gene mutation - Causes X-linked agammaglobulinemia (XLA), which presents with absent B cells and low immunoglobulins. However, it primarily affects males and doesn't typically cause neurological symptoms like ataxia.\n\nB. CD40 ligand deficiency - Causes hyper-IgM syndrome with normal/elevated IgM but low IgG/IgA. Doesn't match the immunoglobulin profile here.\n\nC. AICDA gene mutation - Associated with hyper-IgM syndrome type 2, but B cells are present.\n\nD. RAG1 gene mutation - Causes severe combined immunodeficiency (SCID) with absent B and T cells, but doesn't typically present with progressive neurological symptoms.\n\nE. ATM gene mutation - Causes Ataxia-Telangiectasia, characterized by progressive cerebellar ataxia, oculomotor apraxia, immunodeficiency with low IgA, IgG2, and absent B cells. This matches the neurological symptoms (ataxia, cerebellar atrophy) and immunological findings.\n\nThe answer is (E)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-009", "question": "A 55-year-old man with alcoholic cirrhosis presents with hepatic encephalopathy refractory to lactulose and rifaximin. He has recurrent episodes requiring hospitalization every 2-3 weeks. Transjugular intrahepatic portosystemic shunt (TIPS) is not an option due to severe pulmonary hypertension. Which of the following interventions has the strongest evidence for reducing recurrent hepatic encephalopathy in this patient?", "options": ["Daily polyethylene glycol 3350 17 g", "Empirical vancomycin 125 mg four times daily", "Oral L-ornithine L-aspartate 6 g three times daily", "Sodium benzoate 5 g twice daily", "Branch-chain amino acid supplementation three times daily"], "answer": "A", "answer_index": 0, "explanation": "Polyethylene glycol has been shown in randomized trials to be more effective than lactulose for acute hepatic encephalopathy and may reduce recurrence by more effectively clearing ammonia-producing bacteria from the gut. Vancomycin has similar efficacy to rifaximin but risk of resistance. L-ornithine L-aspartate has modest benefit as adjunct only. Sodium benzoate is second-line. Branch-chain amino acids improve nutrition but not specifically encephalopathy recurrence.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to evaluate the evidence for each intervention in managing refractory hepatic encephalopathy in a patient with alcoholic cirrhosis.\n\nA. Polyethylene glycol (PEG) 3350 - While PEG has shown some benefit in acute hepatic encephalopathy, there's limited evidence for its long-term use in preventing recurrent episodes.\n\nB. Empirical vancomycin - This antibiotic is primarily used for C. difficile infection and has no established role in preventing recurrent hepatic encephalopathy.\n\nC. L-ornithine L-aspartate (LOLA) - LOLA has demonstrated efficacy in multiple studies for reducing ammonia levels and improving hepatic encephalopathy. It works by enhancing ammonia detoxification in the liver and muscle. Several randomized controlled trials support its use in recurrent hepatic encephalopathy.\n\nD. Sodium benzoate - This medication can serve as an alternative ammonia-lowering agent, but has less robust evidence compared to LOLA and is generally considered a third-line agent.\n\nE. Branch-chain amino acid (BCAA) supplementation - While BCAAs have some evidence supporting their use in hepatic encephalopathy, particularly in improving nutritional status in cirrhotic patients, the evidence for preventing recurrent episodes is not as strong as for LOLA.\n\nBased on the available evidence, L-ornithine L-aspartate has the strongest support for reducing recurrent hepatic encephalopathy in this clinical scenario.\n\nThe answer is (C)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-010", "question": "A 34-year-old woman with metastatic HER2-positive breast cancer on trastuzumab, pertuzumab, and docetaxel presents with acute decompensated heart failure. Echocardiography shows global hypokinesis with LVEF 20%, markedly reduced from baseline 55%. Which of the following biomarkers would be most specific for differentiating trastuzumab-induced cardiomyopathy from anthracycline-like toxicity?", "options": ["Elevated serum troponin I with normal NT-proBNP", "Markedly elevated NT-proBNP with normal troponin", "Elevated soluble ST2 with normal galectin-3", "Increased urinary 8-hydroxy-2'-deoxyguanosine", "Elevated growth differentiation factor-15 (GDF-15)"], "answer": "A", "answer_index": 0, "explanation": "Trastuzumab-induced cardiotoxicity typically presents with elevated troponin (indicating myocyte injury) but relatively preserved NT-proBNP (less volume overload/stretch), reflecting its mechanism of reversible HER2 receptor blockade without direct cellular damage. Anthracycline toxicity shows both elevated troponin and markedly elevated NT-proBNP due to irreversible cellular damage. ST2 and galectin-3 are fibrosis markers not specific to this distinction. 8-OHdG is oxidative stress marker. GDF-15 is elevated in various cardiac conditions.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To differentiate trastuzumab-induced cardiomyopathy from anthracycline-like toxicity, I need to consider the distinct mechanisms of cardiotoxicity for each agent.\n\nTrastuzumab (HER2 inhibitor) causes reversible cardiac dysfunction through inhibition of HER2 signaling in cardiomyocytes, without causing significant cell death or permanent structural damage. This typically manifests as functional changes without significant myocardial necrosis.\n\nAnthracyclines cause irreversible damage through oxidative stress, mitochondrial dysfunction, and direct DNA damage, resulting in cardiomyocyte death and permanent structural changes.\n\nLooking at the biomarkers:\n\nA. Elevated troponin I with normal NT-proBNP - Troponin elevation indicates myocardial injury, more typical of anthracycline toxicity.\n\nB. Elevated NT-proBNP with normal troponin - This pattern suggests cardiac dysfunction without significant myocardial necrosis, consistent with trastuzumab-induced cardiotoxicity.\n\nC. Elevated soluble ST2 with normal galectin-3 - These are markers of cardiac fibrosis and remodeling, not specific to either toxicity.\n\nD. Increased urinary 8-hydroxy-2'-deoxyguanosine - This is a marker of oxidative DNA damage, more associated with anthracycline toxicity.\n\nE. Elevated GDF-15 - This is a non-specific marker of cellular stress.\n\nThe pattern of elevated NT-proBNP (indicating cardiac wall stress) with normal troponin (indicating absence of myocardial necrosis) is most specific for trastuzumab-induced cardiotoxicity versus anthracycline damage.\n\nThe answer is (B)"}]